Moderna said on Monday it has started a U.S. government-backed late-stage trial to assess its COVID-19 vaccine candidate in about 30,000 adults who do not have the respiratory illness caused by the new coronavirus.
Cambridge, Massachusetts-based Moderna's shares were up 11% at $81.31 before the bell.
The trial, named COVE, is the first to be implemented under the U.S. government's Operation Warp Speed that aims to accelerate the development, manufacturing and distribution of therapeutics and vaccines for COVID-19.
The federal government is supporting Moderna's vaccine project with nearly a billion dollars and has chosen it as one of the first to enter large-scale human trials.
The main goal of the study will be prevention of the symptomatic COVID-19 disease, the company said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
US Backs Moderna, Says Government Should Face Covid Vaccine Lawsuit UK Approves An Updated Moderna Vaccine Which Targets Omicron Variant US Approves Covid Vaccines For Children As Young As 6 Months 3 Students Dead After Flooding In Delhi Coaching Centre Basement At Olympics Opening Ceremony, Drag Parody Of 'The Last Supper' Draws Flak Kamala Harris Cuts Down Donald Trump's Lead Sharply, Show Latest Polls Will Quit Politics If Attempts Are Made To Disturb Reservation: Praful Patel DSSSB Exam Schedule 2024 Released For Recruitment To Various Posts AAP's Atishi Calls For Meeting After Delhiites Complain Of Blue Tap Water Track Latest News Live on NDTV.com and get news updates from India and around the world.